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Abstract
Background: Determine global gene dysregulation affecting 4q-linked (FSHD-1) and non 4q-linked (FSHD-2) cells during
early stages of myogenic differentiation. This approach has been never applied to FSHD pathogenesis.
Methodology/Principal Findings: By in vitro differentiation of FSHD-1 and FSHD-2 myoblasts and gene chip analysis we
derived that gene expression profile is altered only in FSHD-1 myoblasts and FSHD-2 myotubes. The changes seen in FSHD-
1 regarded a general defect in cell cycle progression, probably due to the upregulation of myogenic markers PAX3 and
MYOD1, and a deficit of factors (SUV39H1 and HMGB2) involved in D4Z4 chromatin conformation. On the other hand, FSHD-
2 mytubes were characterized by a general defect in RNA metabolism, protein synthesis and degradation and, to a lesser
extent, in cell cycle. Common dysregulations regarded genes involved in response to oxidative stress and in sterol
biosynthetic process. Interestingly, our results also suggest that miRNAs might be implied in both FSHD-1 and FSHD-2 gene
dysregulation. Finally, in both cell differentiation systems, we did not observe a gradient of altered gene expression
throughout the 4q35 chromosome.
Conclusions/Significance: FSHD-1 and FSHD-2 cells showed, in different steps of myogenic differentiation, a global
deregulation of gene expression rather than an alteration of expression of 4q35 specific genes. In general, FSHD-1 and
FSHD-2 global gene deregulation interested common and distinctive biological processes. In this regard, defects of cell
cycle progression (FSHD-1 and to a lesser extent FSHD-2), protein synthesis and degradation (FSHD-2), response to oxidative
stress (FSHD-1 and FSHD-2), and cholesterol homeostasis (FSHD-1 and FSHD-2) may in general impair a correct myogenesis.
Taken together our results recapitulate previously reported defects of FSHD-1, and add new insights into the gene
deregulation characterizing both FSHD-1 and FSHD-2, in which miRNAs may play a role.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD [OMIM
158900]) is the third most frequent form of muscle diseases,
inherited as an autosomal dominant trait, with an estimated
incidence of 1 in 20,000.
The disease is predominantly characterized by progressive,
often asymmetric, weakness and wasting of facial, shoulder and
upper arm muscles [1]. Interfamilial and intrafamilial variability,
with severity ranging from asymptomatic carriers (20% of
individuals related to FSHD patients) to loss of ambulation, are
also described [2–3]. Males are on average more often and more
severely affected than females [4].
The molecular defect associated to the disorder has been mapped
to the subtelomeric region of the long arm of chromosome 4 (4q35)
where a large, complex macrosatellite (the D4Z4 repeat array) is
present [5]. In the general population, the D4Z4 repeat array is
polymorphic and it may vary from 11 to more than 100 units of
3.3 kb, whereas most of FSHD patients (FSHD-1) carry only1 to 10
repeat units [6]. To develop FSHD, D4Z4 contraction needs to
occur on a specific genetic background; in fact, only contractions
associated with some chromosome 4 variants, such as the 4qA161
and the newly discovered uncommon 4qA159 and 4qA168, are
permissive [7–8]. It is noticeable that monosomy of 4qter or entire
deletions of D4Z4 repeat array are not associated with the disorder,
so a critical role forthis genomic regionand itsflanking sequencesin
FSHD pathogenesis is to be expected.
However, a small percentage of FSHD cases (,5%) (defined
FSHD-2 patients), shows at least one 4qA161 chromosome but no
contraction of 4q35 D4Z4 [9–10]. This subset of patients appears
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20966very heterogeneous and to date no disease locus has been
identified.
Furthermore, recent studies showed that FSHD-1 and FSHD-2
patients are characterized by 4q D4Z4 hypomethylation that is
contraction-dependent in FSHD-1 and contraction-independent
in FSHD-2 patients [10–11]. Current models of FSHD patho-
genesis suggest that D4Z4 contraction (FSHD-1) or other not yet
known genetic defects (FSHD-2), results in chromatin modification
that could generate aberrant expression of a putative gene
encoded by the D4Z4 repeat, termed double-homeobox 4
(DUX4) [8,12–14], or of genes in cis to the D4Z4 array [15], or
elsewhere in the genome (in trans). However, until now
disagreement remains on whether single genes are reliably mis-
expressed or causative for FSHD.
One approach with no an a priori model on the molecular basis
of the disease is represented by the derivation of global gene
expression profile in cells derived from affected patients in
comparison to control ones. Although several transcriptome
studies have been published on FSHD-1, only one was carried
out on primary myoblasts [16], and none has considered gene
variations in different steps of myogenic differentiation. Further-
more, no studies have been previously reported on global gene
expression in FSHD-2.
In this paper, we present global gene-expression profiles of
myoblasts from FSHD-1 and FSHD-2 patients and healthy
controls in the context of myogenic differentiation.
Materials and Methods
Cell lines and patients
Human primary myoblasts derived from FSHD-1 and FSHD-
2 (non 4q-linked or phenotypic FSHD) patients and from
healthy controls were obtained from the Telethon BioBank
(Neuromuscular Disease and Neuroimmunology Unit, Muscle
Cell Biology Laboratory, C. Besta Neurological Institute).
Table 1 reports the main features of the used cell lines. Cells
Table 1. Features of the analyzed cell lines.
CELL
LINES
AGE AT
BIOPSY/
GENDER
SITE OF
BIOPSY
MOLECULAR
DIAGNOSIS
SIZE OF
D4Z4
ARRAY HAPLOTYPE* PD
a
MICROARRAY
ASSAY**
qRT-
PCR**
FSHD-1
S1
35 / M Quadriceps
femoris
FSHD-1 23 kb 4qA161–4qB168 7 X
FSHD-1
S2
5 / M Quadriceps
femoris
FSHD-1 6–9 kb 4qA161–4qB164 4 X X
FSHD-1
S3
71 / F Quadriceps
femoris
FSHD-1 27,5 kb 4qA161–4A163 5 X X
FSHD-1
S4
55 / F Quadriceps
femoris
FSHD-1 29 kb 4qA161–4qA161 3 X X
FSHD-1
S5
75 / F Quadriceps
femoris
FSHD-1 25 kb N.D. 4 X
FSHD-1
S6
33 / M Quadriceps
femoris
FSHD-1 27,5 kb N.D. 5 X
FSHD-1
S7
17 / F Quadriceps
femoris
FSHD-1 17 kb N.D. 4 X
FSHD-2
S1
12 / M Quadriceps
femoris
FSHD-2 .38 kb 4qA161–4qB168 4 X X
FSHD-2
S2
17 / M Quadriceps
femoris
FSHD-2 .38 kb 4qA161–4qA161 3 X X
CN-1 62 / F Quadriceps
femoris
control - 4qA161–4qB164 5 X
CN-2 77 / M Quadriceps
femoris
control - 4qA161–4qB164 4 X
CN-3 55 / F Quadriceps
femoris
control - 4qA168–4qB164 4 X X
CN-4 60 / M Quadriceps
femoris
control - 4qA161–4qB163 3 X
CN-5 20 / M Quadriceps
femoris
control - N.D. 2 X
CN-6 28 / F Quadriceps
femoris
control - 4qA161–4qB163 5 X
CN-7 37 / F Quadriceps
femoris
control - 4qA161–4qB164 6 X
CN-8 49 / F Quadriceps
femoris
control - N.D. 10 X
N.D. Not determined.
aPopulation doubling (PD).
*Sequence-lengh polymorphism (SSLP) located 3,5 kb proximal to D4Z4 [7].
**Cell lines used in microarray assay and/or qRT-PCR.
doi:10.1371/journal.pone.0020966.t001
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containing 20% fetal bovine serum (FBS), L-glutamine (1%),
penicillin and streptomycin (1%) (Euroclone), insulin 10 mg/ml
(Sigma), human fibroblast growth factor (hFGF) 25 ng/ml and
human epidermal growth factor (hEGF) 10 ng/ml (Peprotech).
Myotubes were obtained after treatment in DMEM supple-
mented with 2% horse serum (Euroclone) and 1% insulin
(Sigma), for 8 days (differentiating medium) [17]. All experi-
ments were performed using cell lines between 2 and 10
population doubling (PD) to avoid premature replicative
senescence which normally occurs after 10–15 PD (Table 1).
All FSHD patients satisfied the accepted clinical criteria for
FSHD. FSHD-1 had undergone DNA diagnosis and were
identified as carriers of small (,38 kb, ,11 repeats) 4q35-
located D4Z4 repeat arrays, as determined by p13E-11
hybridization to EcoRI-digested and EcoRI/BlnI-digested geno-
mic DNA (Table 1). FSHD-2 patients were considered those
showing: a) FSHD clinical signs [18] and b) a 4q D4Z4 cluster
size higher than 38 kb (Table 1). Regarding the clinical signs,
FSHD-2 S1 presented with severe shoulder (involving trapezius,
arm rotator and extension muscles) and pelvic (mainly gluteus)
girdle weakness, as well as a marked facial weakness. FSHD-2
S2 presented with severe shoulder girdle weakness (inability to
lift arms above shoulder level), orbicularis oculi and orbicularis
oris weakness and modest pelvic girdle weakness. Furthermore,
both FSHD-2 patients were subjected to molecular analysis on
Calp-3 and dysferlin gene products (molecular markers of the
two main forms of Limb girdle dystrophies: LGMD2A and
LGMD2B), and the two markers were found unaffected.
Total RNA extraction and qRT-PCR analysis
Total RNA was isolated from sub confluent cell cultures using
the RNeasy Mini Kit (Qiagen), and the purified RNA was
treated with RNase-free DNase (Qiagen) to remove any residual
DNA. Purified RNA was quantified by NanoDrop spectropho-
tometry (Thermo Scientific). Quantitative RT-PCR (qRT-PCR)
analysis was performed on an IQ
TM5 Multicolor Real-Time
PCR Detection System (Biorad) by TaqManH Gene Expression
Assays (Applied Biosystem) (Table 2), or SYBR Green (Biorad)
(Table 3). Each amplicon was analyzed in duplicate in 96-well
optical plates. For TaqManH Gene Expression Assays, typical
20 ml reactions contained 10 ml IQ multiplex supermix (Biorad),
1 ml 20x TaqMan Gene Expression Assay Mix (containing
unlabeled PCR primers and FAM dye-labeled MGB probe;
Applied Biosystem), and 20 ng of cDNA. SYBR Green qRT-
PCR was performed as previously described [17]. For the
TaqManH Assay Thermal cycling conditions were 2 min at
95uC, followed by 40 cycles at 95uC for 10 s and 60uCf o r3 0s .
PCR conditions for SYBR Green assay are described in Table 3.
Each experiment was performed on three independent RNA
extractions of the same sample. For SYBR Green assays,
standard curves for each amplicon were generated using cDNA
derived from a serial 5 fold dilution of human muscle cDNA,
derived from a commercial RNA (Ambion). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), hypoxanthine phosphor-
ibosyl transferase-1 (HPRT1) and polymerase RNA II DNA-
directed polypeptide A (POLR2A) were initially tested as house-
keeping genes. Since they displayed a similar expression range
(data not shown), we decided to use only GAPDH. Thus results
were normalized to PCR product for GAPDH using the
comparative 2
-DDCt m e t h o da n da r ep r e s e n t e da sf o l dc h a n g e
(FC) [19].
The statistical analysis was performed using a two-tailed
Student’s t-test and the error bar is ERR.STD.
Microarray Assay
RNA quality and quantity were assessed using Agilent 2100
Bioanalyzer (Agilent Technologies) and NanoDrop ND-1000
Spectrophotometer (Thermo Fisher Scientific), respectively. 1 mg
of total RNA was subjected to ribosomal RNA removal using
RiboMinus human/mouse transcriptome isolation kit (Invitrogen),
then cDNA was synthesized using Whole-Transcript Sense Target
Labeling Assay (AffymetrixH), following manufacturer’s procedure.
Fragmented biotin-labeled cDNAs were hybridized to AffymetrixH
human exon 1.0 ST arrays at 45uC for 17 hours, as described in
AffymetrixH Users Manual. Washing and staining steps were
carried out using GeneChip Fluidics Station 450, then the arrays
were scanned in the AffymetrixH GeneChipH scanner 3000 7G.
AffymetrixH GeneChipH operating software was used for acqui-
sition, management and initial processing of the expression data,
while arrays quality control was performed using AffymetrixH
Expression Console
TM.
Microarray data analysis
Expression analysis of microarray experiments was performed
with Raw Affymetrix data (".CEL" files) were background
adjusted, preprocessed and normalized using RMA procedure.
The analyses were performed using R statistical environment
(www.r-project.org) with Bioconductor libraries for microarray
data analysis (www.bioconductor.org). Custom probeset defini-
Table 2. TaqMan RT–PCR primers and probes.
Transcript Primer (59–39)
Probes (Reporter –
Quencher)
GAPDH Fw -
cccttcattgacctcaactacatg
TEXAS RED - BHQ-2 (Sigma)
Rw -
tgggatttccattgatgacaagc
POLRA2 Fw- gcaccacgtccaatgacat HEX - BHQ-1 (Sigma)
Rw- gtgcggctgcttccataa
HPRT1 Fw-
agactttgctttccttggtcagg
JOE - TAMRA (Sigma)
Rw-
gtctggcttatatccaacacttcg
KIF18A Hs00229692_m1 FAM - BHQ-2 (Applied
Biosystems)
CDC6 Hs00154374_m1 FAM - BHQ-2 (Applied
Biosystems)
E2F7 Hs00403170_m1 FAM - BHQ-2 (Applied
Biosystems)
SUV39H1 Hs00162471_m1 FAM - BHQ-2 (Applied
Biosystems)
DCLRE1B Hs00224566_m1 FAM - BHQ-2 (Applied
Biosystems)
MSH2 Hs00953523_m1 FAM - BHQ-2 (Applied
Biosystems)
SDR Hs00190538_m1 FAM - BHQ-2 (Applied
Biosystems)
LAMA4 Hs00935293_m1 FAM - BHQ-2 (Applied
Biosystems)
SOD2 Hs00167309_m1 FAM - BHQ-2 (Applied
Biosystems)
PTPRN Hs00160947_m1 FAM - BHQ-2 (Applied
Biosystems)
doi:10.1371/journal.pone.0020966.t002
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ENSEMBL based probeset definition was used to obtain gene
expression data. Expression data matrices were filtered to select
only custom probeset including at least 4 probes. Differential
expression was evaluated using limma package (www.bioconduc-
tor.org) considering the contrasts of interest between selected
groups of samples. Moderated statistics were computed using
limma empirical Bayes adjustment for standard errors. Gene
probesets with P,0.01 and FC.2 were selected in FSHD-1 assay,
whereas P,0.001 and FC.2 were used in FSHD-2, in the
attempt to overcame problems due to the small sample size
analyzed. All data discussed in this publication are MIAME
compliant; all data have been deposited in Gene Expression
Omnibus (NCBI) and are accessible through GEO Series
accession number GSE26061.
Functional classification analysis of the differentially expressed
probes was performed with DAVID Bioinformatics Resource 6.7
(National Institute of Allergy and Infectious Disease (NIAD), NIH
(http://david.abcc.ncifcrf.gov) [21–22], and by Gorilla [23]. We
considered GeneOntology functional classes that had a Fisher
exact p-value (EASE score) ,0.05.
miRNA target prediction
miRNA target prediction was obtained with microRNA.org
(http://www.microrna.org/microrna/home), PicTar (http://pictar.
mdc-berlin.de/), miRNAMap (http://mirnamap.mbc.nctu.edu.tw),
TargetScanHuman 5.1 (http://www.targetscan.org), Microcosm
Target (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/
targets/v5).
Results
Expression profiles of FSHD-1 and FSHD-2 myoblasts and
myotubes
We analyzed by microarray the expression profile of human
primary myoblasts obtained from three FSHD-1 and two
FSHD-2 patients, and three healthy controls (CN). To evaluate
the molecular perturbation of FSHD upon muscle differenti-
ation, we compared patients and CN proliferating myoblasts as
well as the corresponding myotubes obtained after 8 days of cell
differentiation. Moreover we analyzed gene expression varia-
tions in the differentiation processes of FSHD samples and
compared them to that observed in control cells (Fig. 1). Setting
the criteria described in Material and Methods (FC.2a n dp -
value ,0.01 and ,0.001 for FSHD-1 and FSHD-2, respec-
tively), FSHD-1 and FSHD-2 proliferating cells showed a total
of 367 (239 down and 128 up) and 70 (47 down and 23 up)
d e r e g u l a t e dp r o b e sa sc o m p a r e dt oc o n t r o l sr e s p e c t i v e l y ,
sharing only 4 genes (1 down and 3 up) (Fig.1A). The same
analysis performed on the corresponding myotubes (Fig.1B)
evidenced a total of 129 (58 down and 71 up) in FSHD-1 and
626 (448 down and 178 up) in FSHD-2 deregulated probes,
respectively. Also in this case the number of shared genes was
v e r yl o w( 1 3g e n e s ,9d o w na n d4u p ) .T h ef o u rg e n el i s t sa r e
reported in Table S1A-D. Analyzing the gene expression
during the differentiation processes we obtained a total of 559
genes modulated in CN cells, 158 in FSHD-1 and 899 in
FSHD-2 cells. The FSHD-1 differentiation process shared with
the CN one only 67 entries, whereas FSHD-2 and CN
differentiation processes shared 222 entries (Fig.1C). Further-
more, the two pathological differentiation processes shared 25
deregulated genes.
Regarding the 4q35 chromosome region, the analysis did not
reveal a significantly altered pattern of gene expression, in both
FSHD-1 and FSHD-2 samples; exceptions were represented by
three genes (SNX25, ANKRD37 and SORBS2, located approx-
imately 4 Mb upstream to the D4Z4 array) found down-regulated
only in FSHD-1 myotubes (Table S1C).
The probes identified by microarray as up- or down-regulated
in FHSD-1 and FSHD-2 cells were categorized in the DAVID
program (see criteria in Materials and Methods). As shown in
Fig. 2A, the most severely affected biological processes in FSHD-
1 myoblasts in respect to control cells were mainly linked to cell
cycle (94 genes, 35% of total deregulated probes), particularly M-
phase (65 genes out of 94), and to DNA metabolic process (65
genes) and replication (44 genes). More precisely, these classes
that represent the most significant ones (p-value ,10
230)a r e
essentially composed by down-regulated genes. In these biological
categories we found, all down-regulated, seven cell division cycle
genes (CDC, involved in G1/S and G2/M transitions), eight
minichromosome maintenance complex components (MCM,
required for the entry in S phase and cell division), two cyclins
(CCNA2 and CCNF), two cyclin-dependent kinases (CDK1 and
CDK2), several factors involved in DNA replication (four DNA-
dependent DNA polymerases, one primase and one helicase) and
repair (MSH2, DCLRE1B, BRCA1 and BRCA2), eight kinesins
(KIF, involved in spindle formation and the movements of
chromosomes during mitosis), and five centromere proteins
(CEMP). Among the up-regulated genes, of particular interest
was GAS1, involved in growth arrest. Furthermore, the careful
inspection of the deregulated gene list of FSHD-1 myoblasts
allowed the identification of several entries previously reported to
be involved in FSHD-1 and in the myogenic program. We found
the down-regulation of two genes (SUV39H1 and HMGB2)
involved in chromatin conformation mechanism, and the up-
regulation of two myogenic markers (PAX3 and MYOD1) and of
SOD2 involved in oxidative stress response (Table S1A). All
together the above results suggest the occurrence in FSHD-1
myoblasts of a damage in cell cycle progression, and in myogenic
differentiation.
Conversely, the categories of biological processes identified as
more severely affected in FSHD-2 myoblasts (Table S1B) did not
show very significant p-values (.10
23) and were mainly associated
to extracellular structure organization and system development.
Also the functional analysis of FSHD-1 myotubes (Table S1C)
identified a limited number of biological processes, without very
significant p-values (approximately 10
24), essentially involved in
transport and biosynthetic processes.
Differently from what observed in FSHD-1 myotubes, FSHD-
2d i f f e r e n t i a t e dc e l l ss h o w e dt h a tthe most significantly affected
Table 3. SYBR Green Assay primer pairs and PCR efficiency.
Transcript Primer (59–39) Correlation coefficient (R‘2)
Efficiency of reaction (E)
PAX3 Fw- ggagactggctccatacgtc E=99,0%
Rw- caaattactcaaggacgcgg R‘2=0,924
MYOD1 Fw- cggcggaactgctacgaag E=99,5%
Rw- gcgactcagaaggcacgtc R‘2=0,990
MYOG Fw- tcaaccaggaggagcgtgac E=97,0%
Rw- tgtagggtcagccgtgagca R‘2=0,979
MYH2 Fw- ggaccaactgagtgaactgaaa E=95,8%
Rw- ttgcctcttgataactgagacac R‘2=0,908
doi:10.1371/journal.pone.0020966.t003
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metabolic process, including ribosome biogenesis (22 genes) and
tRNA metabolic process (21 genes). Others significantly affected
categories regarded sterol (13 genes) and amino acid metabolic
processes (31 genes) (Fig. 2B). Considering the tRNA metabolic
process, about 50% of all entries were tRNA synthases (ARSs).
Interestingly, in respect to cellular components the DAVID
program highlighted in FSHD-2 myotubes as the main
deregulated the nucleolus (55 genes) and the mitochondrion
(53 genes); almost all the deregulated genes in these categories
were down-regulated. The mitochondrion showed the deregu-
lation of many ribosomal proteins (seven MRPs), four genes
involved in respiratory chain, including ATP synthase, six
t r a n s p o r t e r s( i . e .S L C ,T I M Ma n dT O M M ) ,a n dt h r e eg e n e s
involved in fission and fusion (DNM1L, MTFR1, and MFN2).
Two entries (GSR and GPX4) inv o l v e di nt h er e s p o n s et o
oxidative stress were also found down-regulated. In addition the
inspection of the gene list containing all the deregulated genes
(Table S1D) showed the down-regulation of five eukaryotic
translation initiation factors (EIFs). Thus, FSHD-2 myotubes
were principally affected in functions related to protein
synthesis, to sterol biosynthetic process and to energetic
metabolism. The complete lists of all the significant deregulated
biological categories of the four analyzed cell typologies (FSHD-
1 and FSHD-2 myoblasts and myotubes) are reported in Table
S2A-D.
Another approach to investigate the gene deregulation in
FSHD cells is to analyze the gene chip results in the context of
the differentiation process. This could be obtained by categoriz-
ing in the DAVID program the variation in gene expression
profile obtained analyzing the FSHD-1 and FSHD-2 differenti-
ation processes subtracted with the variation showed by the
control cells differentiation. The result of these analyses is
schematized in Fig.3, where on the left is reported the biological
process not modulated in FSHD-1 (yellow bar) and in FSHD-2
(grey bar) cells, in respect to control, whereas on the right the
biological processes modulated in FSHD-1 (yellow bar) and in
FSHD-2 (grey bars), but not in control cells. Both pathological
Figure 1. Venn diagrams showing overlapping and non-overlapping counts of genes differentially expressed. A): FSHD-1 and FSHD-2
myoblasts, in respect to controls; 367 genes were up- (128) or down- (239) regulated in FSHD-1 myoblasts and 70 genes were up- (23) or down- (47)
regulated in FSHD-2 myoblasts. Four (3 up and 1 down) genes were deregulated in both cell lines. B): FSHD-1 and FSHD-2 myotubes, in respect to
controls; 129 genes were up- (71) or down- (58) regulated in FSHD-1 myotubes and 626 genes were up- (178) or down- (448) regulated in FSHD-2
myotubes. Thirteen (4 up and 9 down) genes were deregulated in both cell lines. C): FSHD-1 and FSHD-2 differentiation processes, in respect to the
differentiation of control cells; 559 genes were modulated in the differentiation of CN cells, 158 in the differentiation of FSHD-1 and 899 of FSHD-2,
cells. FSHD-1 and CN differentiation processes shared 67 entries, whereas FSHD-2 and CN differentiation processes shared 222 entries. FSHD-1 and
FSHD-2 differentiation processes shared 25 deregulated genes. FC.2 and p-value ,0.01 and ,0.001 for FSHD-1 and FSHD-2, respectively.
doi:10.1371/journal.pone.0020966.g001
Expression Profile of FSHD Cell Differentiation
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20966differentiation processes showed as mainly deregulated categories
those already derived in FSHD-1 myoblasts (cell cycle and
proliferation) and FSHD-2 myotubes (RNA processing) (Figs. 2
and 3). In addition, this analysis evidenced a slight damage of cell
cycle also in FSHD-2 and of the proteasomal ubiquitin-
dependent processes. Interestingly, FSHD-1 and FSHD-2 cells
showed the common deregulation of five genes involved in
cholesterol metabolic process; four genes (HMGCR, DHCR7,
DHCR24 and IDI1) implied in cholesterol biosynthesis, were up-
regulated in FSHD-1 and down-regulated in FSHD-2, and one
gene (ABCA1) involved in the efflux of cholesterol from the cell,
was down-regulated in FSHD-1 and upregulated in FSHD-2.
The complete lists of all the significant deregulated biological
categories of the three differentiation processes are reported in
Table S3.
MicroRNA deregulation
The gene expression profile analysis of FSHD-1 and FSHD-2
myoblasts and myotubes also evidenced a total of six deregulated
miRNAs. Two miRNAs, mir-23b and mir-133a-1, were upregu-
lated in FSHD-1 and FSHD-2 myoblasts, respectively; FSHD-1
myotubes showed the down-regulation of one miRNA (mir-186),
whereas in FSHD-2 myotubes four miRNAs (mir-149, mir-15a,
mir26a-2, and mir23b) were up-regulated. Furthermore, mir-23b
was found deregulated both in FSHD-1 myoblasts and FSHD-2
myotubes. The derived list of deregulated miRNAs was then
analyzed for the predicted targeted genes (see Materials and
Methods). To this aim we used five different softwares, and only
the gene targets predicted by at least three softwares and showing
an opposite trend of deregulation in the gene chip analysis were
considered. By using these criteria, the miRNAs 133a-1 was not
further considered. Table 4 reports the five miRNAs and the
corresponding predicted targeted genes found deregulated in
FSHD-1 myoblasts and myotubes and in FSHD-2 myotubes, with
the corresponding fold change and p-value. Interestingly, some of
the predicted targets of the miRNAs deregulated in FSHD-2
myotubes could be included into the functional categories
represented in the Gene Ontology analysis of these samples, such
Figure 2. Selected gene classifications according to biological processes. Biological processes significantly enriched in the set of genes
identified by microarray as up- or down-regulated in A) FSHD-1 myoblasts, and B) in FSHD-2 myotubes, and categorized in the DAVID program.
Numbers in the bars indicate the number of genes assigned to each gene ontology term. p-value ,0.05.
doi:10.1371/journal.pone.0020966.g002
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biosynthesis (SC4MOL). One gene (PRKAR2A) was targeted by
more then one miRNA (asterisked in Table 4).
Validation of microarray results by Quantitative Real–
Time PCR
To confirm the FSHD-1 microarray data we focused our
attention on some genes contained in the most enriched
categories evidenced by GO analysis. The chosen representative
genes were validated by multiplex Real–Time assay performed
with TaqmanH probes on seven FSHD-1 in comparison to six
healthy controls (for a description of the used cell lines see
Table 1 in Materials and Methods). The analyzed genes
comprised: E2F7 (negative regulator of cell cycle progression),
CDC6 (DNA replication), KIF18A (chromosome segregation)
and SUV39H1 (histone methylation), MSH2, DCLRE1B,
SOD2 (DNA damage and repair), LAMA4 (extracellular
matrix), SDR (membrane raft) and PTPRN (cell growth and
differentiation). mir 23-b was also analyzed. As shown in Fig.4A,
the results of the Real–Time assay confirmed the data of the
array. In fact all genes tested were regulated in the same
direction with both methods. The data relative to the FSHD-2
genechip analysis were not validated by qRT-PCR due to the
unavailability of other FSHD-2 cell lines in addition to those
used for microarray experiments.
Furthermore, since the analysis of the FSHD-1 myoblasts gene
chip array evidenced a slight up-regulation of the transcription
factor PAX3 (P 1610
22; FC 2.17), a molecule involved in
developmental myogenesis, and of MYOD (P 1,01610
22;F C
2.39, Table S1A), we also evaluated by real-time PCR the gene
expression level of these and of two other myogenic markers
(MYOG and MYH2) not significantly deregulated in the chip
assay, using cDNAs from FSHD-1 cells before and after
differentiation (day 0 and 8).
As shown in Fig.4B, the expression level of the four myogenic
markers (PAX3, MYOD1, MYOG and MYH2) in control and
FSHD-1 cells showed a general trend of up-regulation upon
differentiation. In FSHD-1 proliferating cells compared to control,
PAX3 and MYOD1 were, respectively almost four and six-fold
up-regulated, respectively; conversely, MYOG and MYH2
mRNA levels were undetectable, both in control and FSHD-1
cells. Upon differentiation, all markers showed comparable levels
of mRNA expression in FSHD-1 and control cells. These results
confirm the general trend of differentiation exhibited by both
control and FSHD-1 cells and that significant differences are only
present in FSHD-1 proliferating cells for PAX3 and MYOD
mRNAs levels. Regarding FSHD-2 cells the gene chip assay data
evidenced for these four myogenic markers an expression level
similar to that of control cells both before and after cell
differentiation (Table S1B and S1D).
Discussion
In this paper we have compared the expression profiles of
FSHD-1 and FSHD-2 precursor cells in regard to healthy controls
before and after myogenic differentiation. In our knowledge, this is
the first report that uses human 4q-linked and non 4q-linked (or
phenotypic) FSHD primary myoblasts and their in vitro
differentiation to investigate global gene deregulation character-
izing cells deriving from FSHD patients with a different genetic
defect, but with a very similar phenotypic manifestation of the
disease [24]. Although the in vitro differentiation of myoblasts does
not involve many of the complex series of events known to be
important in vivo, such as activation of quiescent satellite cells
(stem cell), maturation of the myotubes into muscle fibers and the
innervations of the fibers, the cell system we used could be useful in
the attempt to derive global gene expression deregulation
characterizing the early stages of myogenic differentiation without
interferences represented by cell contamination, inflammation or
muscle regeneration as found in studies of biopsies.
It is noteworthy that only two FSHD-2 cell lines were available
for the chip analysis; although this represents a small sample size
we decided anyhow to include them in our analysis since this type
of FSHD cell has never been analyzed; thus to render the data
more significant we decided to use a lower p value (.0.001) than
that used for FSHD-1 (.0.01).
Figure 3. Selected gene classifications according to biological processes of genes regulated in the three differentiation programs.
Diagram showing the biological processes significantly enriched in the set of genes differentially expressed in the differentiation processes of FSHD-1
(yellow bars) and FSHD-2 (grey bars) cells in respect to control. Bar on the left indicated the biological process modulated in control but not in FSHD-
1 (yellow bar), and FSHD-2 (grey bars) cells, whereas bars on the right indicated the biological processes modulated in FSHD-1 (yellow bar) and FSHD-
2 (grey bars) but not in control cells. All bars group many related GO categories. p-value ,10
24.
doi:10.1371/journal.pone.0020966.g003
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chromosome linked to D4Z4 contraction has been proposed as a
model for the molecular pathogenesis of FSHD-1 [15]. Our
results did not evidence such a correlation in both FSHD-1 and
FSHD-2 cells. Only three genes (SNX25, ANKRD37 and
SORBS2) located approximately from 4 to 5 Mb proximal to
the D4Z4 array showed in FSHD-1 myotubes a significant
down-regulation. Interestingly, one of these genes (ANKRD37)
was also found deregulated in muscle biopsies from FSHD-1
patients [25]. Absence of significant gene expression alteration
throughout the 4q35 region agrees with the data previously
reported by Winokour et al. (2003) [26] and Osborne et al.
(2007) [27] on muscle biopsies, thus excluding a position effect
model for FSHD. However, we can not exclude the possibility
that some of the 4q35 genes (i.e. FRG1) might be transiently
deregulated during intermediate steps of the differentiation
process [17].
However, significant results concerning the altered biological
processes of the pathological cells were obtained, by deriving in
regard to controls the global deregulation of gene expression in
FSHD-1 and FSHD-2 myoblasts and myotubes and by
comparing the two pathological differentiation processes to the
normal one. By combining the two approaches, we derived that
gene deregulation was essentially a feature of FSHD-1 prolifer-
ating cells and of FSHD-2 differentiated cells. FSHD-1 myoblasts
showed a highly significant gene deregulation linked to cell cycle
control essentially affecting G1/S and G2/M transitions. These
results are in agreement with previous data derived by the
analysis of FSHD-1 cells, and showing the up-regulation of p21,
known to arrest progression at G1/S interface, and of WEE1, a
negative regulator of entry into mitosis (G2/M transition)
[16,26].
Furthermore, FSHD-1 myoblasts showed the up-regulation of
PAX3, a key upstream regulator of the myogenic program: PAX3
up-regulates the myogenic determination gene MYOD1 that, in
turn regulates MYOG expression [28]. However, while in
embryonic tissues the ability of PAX3 to activate the myogenic
program is well documented [29-30], in adult-derived cells this
effect is still under discussion.[28,31–32].
In our system, the found premature up-regulation of
MYOD1 mRNA could be ascribed to PAX3 mRNA up-
regulation; furthermore, as previously reported [33], also in our
cellular system MYOD-mediated induction of myogenesis is
accompanied by the down-regulation of cyclins. Thus, PAX3
up-regulation might contribute to the early cell cycle arrest
shown by FSHD-1 myoblasts. In spite of the up-regulation of
MYOD1 mRNA, FSHD-1 proliferating cells did not show the
occurrence of later marker of myogenic differentiation, such as
myogenin and sarcomeric myosin. This could probably due to
the absence of other required transcription factors such as
myogenic enhancer factors (MEFs), essential for muscle
differentiation. Thus, FSHD-1 cells seem to be characterized
by a premature and partial activation of the myogenic program
that could be related to the observed defect in cell cycle
progression.
Remarkably, other two genes SUV39H1 and HMGB2 both
involved in chromatin remodeling were down-regulated in FSHD-
1 myoblasts. SUV39H1 is a histone methyl-transferase involved in
D4Z4 H3K9me3 [34], whereas HMGB2 is part of a multi-protein
complex shown to bind a 27bp binding element (DBE) within
D4Z4 units [15,35]. In normal cells both gene activities, in
association with other factors, may play an important role in the
establishment and maintenance of the higher order chromatin
structure of the D4Z4 array (facultative heterochromatin). In
FSHD-1 cells, the down-regulation of SUV39H1 and HMGB2
genes could correlate with the hypothesized more open chromatin
conformation of the contracted 4q alleles [8,10].
Thus, in addition to the early partial activation of the myogenic
program, proteins involved in chromatin organization are also
modulated in FSHD-1 samples, suggesting that their absence
might contribute to the epigenetic defect of the D4Z4 array.
Conversely, FSHD-2 cells were characterized by a significant
alteration of gene expression only after the in vitro transition from
myoblasts to myotubes. Effectively, FSHD-2 myotubes showed the
Table 4. miRNAs significantly dysregulated in FSHD-1 and FSHD-2 myoblasts and myotubes, with the corresponding predicted
gene targets.
miRNA GENE TARGET
CELL
LINES
GENE
SYMBOL FC (P-VALUE)
GENE
SYMBOL FC (P-VALUE) FUNCTION
FSHD-1
myoblasts
hsa-mir-23b 3,4 (6,90E-03) HMGB2 22,1 (1,91E-03) Chromatin conformation
FSHD-1
myotube
hsa-mir-186 22,3 (2,09E-03) HAS2 3,8 (1,48E-03) Biosynthesis of extracellular matrix
FSHD-2
myotubes
hsa-mir-149 3,18 (4,22E-05) NFIB
PRKAR2A*
25,77(2,41E-05)
22,48 (2,43E-04)
RNA biosynthesis
Signal transduction
FSHD-2
myotubes
hsa-mir-15a 6,19 (6,07E-05) IARS
COPS7A
PRKAR2A*
ARL2
23,03 (8,95E-06)
22,23 (1,35E-05)
22,48 (2,43E-04)
22,54 (4,76E-04)
Protein synthesis
Signal transduction
Signal transduction
Transport
FSHD-2
myotubes
hsa-mir-26a-2 2,64 (5,80E-04) EPC2
ZNF410
FAM55C
SC4MOL
22,95 (5,67E-05)
22,33 (1,91E-04)
23,30 (3,97E-04)
27,49 (1,13E-05)
Chromatin conformation; regulation of transcription
RNA biosynthesis
Unknown
Cholesterol byosinthesis
FSHD-2
myotubes
hsa-mir-23b 6,57 (6,79E-04) EPS15
ENTPD5
22,28 (9,07E-04)
22,27 (1,67E-04)
Transport
Nucleotide metabolism
*The asterisk indicates the only gene targeted by more than one miRNA.
doi:10.1371/journal.pone.0020966.t004
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metabolism and in nucleolus organization, implied in protein
synthesis. FSHD-2 myotubes also showed mitochondrial abnor-
malities, including energy production, response to oxidative stress
and mitochondrial dynamics. Mitochondrial abnormalities and
dysfunction in protein synthesis have been also reported for other
muscular dystrophies [36-39].
FSHD-2 differentiation analysis also evidenced the deregulation
of the cell cycle and of proteasomal ubiquitin-dependent process.
Importantly, ubiquitin-dependent proteolysis has been suggested
Figure 4. Real-Time PCR validation of FSHD-1 microarray data. A: Table reports the genes analyzed in qRT-PCR with fold-change and p-value.
The data obtained in the FSHD-1 myoblasts gene chip array and the biological processes identified by the DAVID program, are also reported. The
analysis was performed on seven FSHD-1 and six CN myoblast cell lines. B) Bar diagrams show relative expression of PAX3, MYOD1, MYOG and MYH2
in control and FSHD-1 myoblasts (day 0) and myotubes (day 8) relative to GAPDH. *** p-value , ,001.
doi:10.1371/journal.pone.0020966.g004
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division and differentiation [40].
Interestingly, both FSHD-1 and FSHD-2 cells were affected in
sterol biosynthetic process, showing the deregulation, although in
the opposite direction, of the same genes. The alteration of
cholesterol homeostasis could primarily cause cell damage in
membranes lipid rafts, where different proteins are incorporate
(e.g. GPI-anchored and cholesterol-linked proteins), and in
caveolae a subclass of rafts [41]. It was previously reported that
caveolae structure alteration could affect myotube formation [42–
43], and that FSHD-1 biopsies are characterized by the
impairment of biological processes involved in the synthesis of
GPI anchored proteins [25].
In normal cells reactive oxygen species (ROS) generation is
counterbalanced by the action of antioxidant enzymes, such as
mitochondrial superoxide dismutase (SOD2) and of those involved
in glutathione metabolism. The found deregulation of SOD2 in
FSHD-1 myoblasts and of glutathione reductase (GSR) and
peroxidase (GPX4) in FSHD-2 myotubes could suggest for both
FSHD manifestations the occurrence of a similar increased
susceptibility to oxidative stress. The deregulation of enzymes
involved in oxidative stress resistance and the consequent
increased susceptibility to oxidative stress have been already
reported for FSHD-1 myoblasts and biopsies [16,26–27,44].
Finally, both FSHD-1 and FSHD-2 cells showed the involve-
ment in the gene deregulation network of some microRNAs
(miRNA), a class of molecules previously shown to play an
important role in the regulation of muscle development [45].
Among a total of five miRNAs found deregulated in the present
work, two (mir186 and mir15a) were previously reported to be
commonly deregulated in more than three (including FSHD) types
of muscular disorders [46]. The remaining three miRNAs were
detected in FSHD-1 myoblasts (mir-23b) and in FSHD-2
myotubes (mir-149, mir-26a2 and mir-23b). Interestingly, one
predicted target of the supposedly FSHD-specific miRNA 23b is a
gene involved in the chromatin conformation of the 4q D4Z4
array (HMGB2 down-regulated in FSHD-1 myoblasts) [15].
Although future work is certainly needed to confirm the herein
derived observations, taken together our results seem to recapit-
ulate previously reported defects of FSHD-1, and to add new
insights into the gene deregulation characterizing both FSHD-1
and FSHD-2. In general, FSHD-1 cells showed an alteration of
cell cycle control, a defect in cholesterol homeostasis and
presumably in the mitochondrial capacity to buffer oxidative
stress. With the exception of cholesterol homeostasis, FSHD-2 cells
shared all these features by deregulating different genes. FSHD-2
cells also showed a general deregulation of protein synthesis and
degradation. In this regard, proteasome ubiquitin-dependent
protein degradation could be viewed as an impairment in exit
from the cell cycle. Thus both FSHD manifestations presented
cellular deficiencies that do not arise from a 4q position effect
mechanism, but rather from a general alteration of gene
expression in which miRNA deregulation may play a role.
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